Hq Spclt Pharma Company Profile

✉ Email this page to a colleague

HQ SPCLT PHARMA has fifteen approved drugs.

There are six US patents protecting HQ SPCLT PHARMA drugs.

There are twelve patent family members on HQ SPCLT PHARMA drugs in nine countries and one hundred and four supplementary protection certificates in sixteen countries.

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hq Spclt Pharma	MEROPENEM	meropenem	INJECTABLE;INJECTION	210773-001	Aug 16, 2019	AP	RX	No	No		⤷ Start Trial				⤷ Start Trial
Hq Spclt Pharma	TAXOL	paclitaxel	INJECTABLE;INJECTION	020262-001	Dec 29, 1992		DISCN	Yes	No		⤷ Start Trial				⤷ Start Trial
Hq Spclt Pharma	LINEZOLID	linezolid	SOLUTION;INTRAVENOUS	207001-001	Jul 7, 2017	AP	RX	No	No		⤷ Start Trial				⤷ Start Trial
Hq Spclt Pharma	DEXMEDETOMIDINE HYDROCHLORIDE	dexmedetomidine hydrochloride	SOLUTION;INTRAVENOUS	206628-004	Jun 22, 2018		RX	Yes	No	9,649,296	⤷ Start Trial	Y			⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Hq Spclt Pharma	TAXOL	paclitaxel	INJECTABLE;INJECTION	020262-001	Dec 29, 1992	6,096,331	⤷ Start Trial
Hq Spclt Pharma	TAXOL	paclitaxel	INJECTABLE;INJECTION	020262-001	Dec 29, 1992	5,641,803	⤷ Start Trial
Hq Spclt Pharma	PLATINOL	cisplatin	INJECTABLE;INJECTION	018057-001	Approved Prior to Jan 1, 1982	4,177,263	⤷ Start Trial
Hq Spclt Pharma	CISPLATIN	cisplatin	INJECTABLE;INJECTION	018057-004	Nov 8, 1988	4,177,263	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1853250	C300673	Netherlands	⤷ Start Trial	PRODUCT NAME: PACLITAXEL, GEFORMULEERD ALS ALBUMINE-GEBONDEN NANODEELTJES; REGISTRATION NO/DATE: EU/1/07/428/001-002 20131220
2957286	1990003-4	Sweden	⤷ Start Trial	PRODUCT NAME: PATIROMER SORBITEX CALCIUM; FIRST MARKETING AUTHORIZATION NUMBER SE: EG EU/1/17/1179, 2017-07-21; PRV HAR I BESLUT DEN 16 JULI 2025 RAETTAT SKYDDSTIDEN I FOELJANDE TILLAEGGSSKYDD I ENLIGHET MED PMD:S BESLUT PMAE 7804/24: 1990003-4 2190008-9
0720599	CR 2014 00050	Denmark	⤷ Start Trial	PRODUCT NAME: EZETIMIBE AND ATORVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING ATORVASTATIN AS ATORVASTATIN CALCIUM TRIHYDRATE; REG. NO/DATE: DE/H/3895-3898/001-004/DC 20140910
2666774	CA 2020 00037	Denmark	⤷ Start Trial	PRODUCT NAME: RELEBACTAM, OPTIONALLY IN THE FORM OF THE MONOHYDRATE, IMIPENEM AND CILASTATIN, OPTIONALLY IN THE FORM OF THE SODIUM SALT; REG. NO/DATE: EU/1/19/1420 20200217
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.